informaworld logo
HOME . ABOUT US . CONTACT US 		HELP . PUBLISH WITH US . LIBRARIANS 
ebooks logo journals logo reference works logo abstract databases logo
bullet  SIGN IN Register | Why Register? | Got a Voucher? alerts   marked lists   shopping cart 
Advert: Informa Healthcare - http://www.informahealthcare.com

informaworld

HOME   |   SEARCH   |   BROWSE
    Issues List       Latest Issue       Forthcoming Articles       Volume 49 Issue 4       Aims & Scope       Editorial Board       Instructions for Authors       Subscribe      
<< earliestearliest   < prevprev   Issue listissues   next >next   latest >>latest
Publisher Logo Publication Cover
Search within this journal

Leukemia and Lymphoma, Volume 49 Issue 4 2008

Leukemia and Lymphoma is moving!
2008 Impact Factor: 1.939 (© Thomson Reuters, Journal Citation Reports®, 2009)
ISSN: 1029-2403 (electronic) 1042-8194 (paper)
Publication Frequency: 12 issues per year
Viewing the Journal: Select the initial letter of your research topic from the list below, or enter your search term on the left.
Sort by: Title | Page | Author
< Previous • 1 • 2 • Next >
View new articles ahead of the print edition
select-down Click for help
Preface
Targets and targeted drugs in chronic myeloid leukemia
Peter Valent
Page 599
Abstract | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Focused Reviews in CML
Requirement of lipocalin 2 for chronic myeloid leukemia
Ralph Arlinghaus; Xiaohong Leng
Pages 600 – 603
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia
Peter Valent; Michael Deininger
Pages 604 – 609
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts
Tomasz Skorski
Pages 610 – 614
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Oliver Hantschel;  Uwe Rix; Giulio Superti-Furga
Pages 615 – 619
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Signal interception-based therapies – A double-edged sword in Bcr/abl-induced malignancies?
Eva Zebedin;  Michael Freissmuth; Veronika Sexl
Pages 620 – 624
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
New therapeutic approaches and prognostic factors in chronic myeloid leukemia
Giuseppe Saglio;  Stefano Ulisciani;  Marco Bosa;  Daniela Cilloni; Giovanna Rege-Cambrin
Pages 625 – 628
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Immunotherapeutic approaches in chronic myelogenous leukemia
François Guilhot;  Lydia Roy;  Pierre-Jean Saulnier;  Joëlle Guilhot;  Anne Barra;  Jean-Marc Gombert; Ali Turhan
Pages 629 – 634
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia
Peter Valent;  Hermine Agis;  Wolfgang Sperr;  Christian Sillaber; Hans-Peter Horny
Pages 635 – 638
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia
Richard E. Clark;  Andrea Davies;  Munir Pirmohamed; Athina Giannoudis
Pages 639 – 642
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia
Stefan Schmidt;  Guenther Gastl; Dominik Wolf
Pages 643 – 647
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Commentaries
Chronic lymphocytic leukemia with mutated IgVH1-69 usage: A distinct CLL subgroup with more indolent behavior?
Elena M. Hartmann; Andreas Rosenwald
Pages 648 – 649
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
DNA methyltransferase inhibitors: Class effect or unique agents?
Elizabeth A. Griffiths; Steven D. Gore
Pages 650 – 651
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
The development of novel immunotherapeutic approaches in multiple myeloma
Stefan Peinert;  H. Miles Prince; Simon Harrison
Pages 652 – 654
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Mantle, blastic, Burkitt
John Anastasi
Pages 655 – 656
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Bortezomib: Putting mantle cell lymphoma on death row
Andrew H. Wei; Andrew W. Roberts
Pages 657 – 658
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Reviews
Early interim PET scan in Hodgkin lymphoma: Where do we stand?
Andrea Gallamini;  Martin Hutchings;  Abraham Avigdor; Aaron Polliack
Pages 659 – 662
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Current treatment approaches for diffuse large B-cell lymphoma
Tim Illidge; Shaun Tolan
Pages 663 – 676
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
Novel anti-myeloma agents and angiogenesis
Konstantinos Anargyrou;  Meletios-Athanassios Dimopoulos;  Orhan Sezer; Evangelos Terpos
Pages 677 – 689
Abstract | References | Full Text PDF | Full Text HTML | Request Permissions
Related Articles 		 buy now buy now
select-up

Privacy Policy | Terms & Conditions | Accessibility | RSS
FAQs in: English . Français . Español . 中文（简体和繁體）
© 2009 Informa plc